Ethical preparedness of data monitoring committees (DMCs) to oversee international clinical trials: a qualitative descriptive study

被引:0
|
作者
Hinga, Alex [1 ]
Ibrahim, Akram [2 ]
Vintimilla, Diego [3 ]
Jones, Mickayla [2 ]
Eckstein, Lisa [4 ]
Rid, Annette [5 ,6 ]
Shah, Seema K. [2 ,7 ]
Kamuya, Dorcas [1 ,8 ]
机构
[1] KEMRI Wellcome Trust Res Programme, Hlth Syst & Res Eth, Nairobi, Kenya
[2] Ann & Robert H Lurie Childrens Hosp Chicago, Stanley Manne Childrens Res Inst, Mary Ann & J Milburn Smith Child Hlth Outcomes Res, Chicago, IL USA
[3] Chicago Dept Publ Hlth, Chicago, IL USA
[4] Univ Tasmania, Sch Law, Hobart, Tas, Australia
[5] NIH, Clin Ctr, Dept Bioeth, Bethesda, MD USA
[6] NIH, Fogarty Int Ctr, Div Int Sci Policy Planning & Evaluat, Bethesda, MD USA
[7] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL USA
[8] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med, Oxford, England
来源
BMJ GLOBAL HEALTH | 2024年 / 9卷 / 08期
基金
美国国家卫生研究院;
关键词
Global Health; Qualitative study; Clinical trial; Decision Making; Descriptive study; SAFETY; BOARDS; ISSUES;
D O I
10.1136/bmjgh-2024-015233
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction A data monitoring committee (DMC) is an independent group of experts who assess the ongoing scientific and ethical integrity of a study through periodic analyses of study data. The objective of this study was to explore the extent to which the structure, membership and deliberations of DMCs enable them to address ethical issues.Methods We conducted qualitative individual interviews (n=22) with DMC members from countries across Africa, the Americas, South Asia and the UK. We selected interview respondents through purposive sampling, managed data using NVivo (Release V.1.7) and analysed data thematically.Results All respondents were highly experienced professionals; many (18/22) had received training in medicine and/or statistics. One respondent had academic qualifications in ethics, and four indicated that they served on DMCs as ethicists. While respondents generally felt DMCs should be required for studies that were high-risk or enrolled vulnerable populations, some were concerned about the overuse of DMCs. There were divergent views on the necessity of geographical and disciplinary representation in DMC membership, including about whether ethicists were helpful. Many respondents described a DMC member recruitment process that they felt was somewhat exclusive. While one respondent received DMC-specific training, most described learning on the job. Respondents generally agreed that study protocols and DMC charters were key guiding documents for addressing ethical issues and described DMC deliberations that often, but not always, involved consensus-building.Conclusion This study is one of the first to consider the ethical implications of DMC structure, membership and deliberations. The potential overuse of DMCs, DMC member recruitment processes that seem somewhat insular, limited training for DMC members, and divergent approaches to deliberation may limit the capacity of DMCs for addressing ethical issues. Further research on DMC structure and processes could help enhance the ethical preparedness of DMCs.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] STUDY DISCONTINUATIONS IN CLINICAL TRIALS AND DATA MONITORING COMMITTEES
    Fischer, T.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 : 37 - 37
  • [2] Data monitoring committees for pragmatic clinical trials
    Ellenberg, Susan S.
    Culbertson, Richard
    Gillen, Daniel L.
    Goodman, Steven
    Schrandt, Suzanne
    Zirkle, Maryan
    CLINICAL TRIALS, 2015, 12 (05) : 530 - 536
  • [3] Data and Safety Monitoring Committees in Clinical Trials
    Rehman, Andrea M.
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY, 2010, 173 : 466 - 467
  • [4] Data monitoring committees and randomized clinical trials
    Trachtman, Howard
    Caplan, Arthur L.
    KIDNEY INTERNATIONAL, 2019, 95 (04) : 992 - 992
  • [5] DATA-MONITORING COMMITTEES IN CLINICAL-TRIALS
    SLEIGHT, P
    LANCET, 1993, 341 (8854): : 1219 - 1220
  • [6] SAFETY AND DATA MONITORING COMMITTEES FOR CLINICAL-TRIALS
    CONTI, CR
    CLINICAL CARDIOLOGY, 1995, 18 (08) : 432 - 432
  • [7] On independent data monitoring committees in oncology clinical trials
    Wittes, Janet
    Schactman, Mark
    CHINESE CLINICAL ONCOLOGY, 2014, 3 (03)
  • [8] Reporting of data monitoring committees and adverse events in paediatric trials: a descriptive analysis
    Gates, Allison
    Caldwell, Patrina
    Curtis, Sarah
    Dans, Leonila
    Fernandes, Ricardo M.
    Hartling, Lisa
    Kelly, Lauren E.
    Vandermeer, Ben
    Williams, Katrina
    Woolfall, Kerry
    Dyson, Michele P.
    BMJ PAEDIATRICS OPEN, 2019, 3 (01)
  • [9] Preparedness for a first clinical placement in nursing: a descriptive qualitative study
    Marriott, Philippa H. M.
    Weller-Newton, Jennifer M.
    Reid, Katharine J.
    BMC NURSING, 2024, 23 (01):
  • [10] Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees
    Dixon, Dennis O.
    Freedman, Ralph S.
    Herson, Jay
    Hughes, Michael
    Kim, KyungMann
    Silverman, Michael H.
    Tangen, Catherine M.
    CLINICAL TRIALS, 2006, 3 (03) : 314 - 319